In the last trading session, 1.17 million Heron Therapeutics Inc (NASDAQ:HRTX) shares changed hands as the company’s beta touched 1.33. With the company’s per share price at $2.34 changed hands at $0.01 or 0.43% during last session, the market valuation stood at $356.45M. HRTX’s last price was a discount, traded about -67.95% off its 52-week high of $3.93. The share price had its 52-week low at $1.04, which suggests the last value was 55.56% up since then. When we look at Heron Therapeutics Inc’s average trading volume, we note the 10-day average is 0.98 million shares, with the 3-month average coming to 1.66 million.
Analysts gave the Heron Therapeutics Inc (HRTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HRTX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX was in green as seen at the end of in last trading. With action 8.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 52.94%, with the 5-day performance at 8.84% in the green. However, in the 30-day time frame, Heron Therapeutics Inc (NASDAQ:HRTX) is 3.54% up. Looking at the short shares, we see there were 32.96 million shares sold at short interest cover period of 24.96 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 66.57% from its current market value. According to analyst projections, HRTX’s forecast low is 5 with 9 as the target high. To hit the forecast high, the stock’s price needs a -284.62% plunge from its current level, while the stock would need to soar -113.68% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.68%. The 2025 estimates are for Heron Therapeutics Inc earnings to increase by 81.81%.
HRTX Dividends
Heron Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.80% of Heron Therapeutics Inc shares while 75.91% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.52%. There are 75.91% institutions holding the Heron Therapeutics Inc stock share, with RUBRIC CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 17.5395% of the shares, roughly 26.71 million HRTX shares worth $93.5 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.657% or 8.62 million shares worth $30.16 million as of 2024-06-30.
